Atara Biotherapeutics, Inc. (ATRA)

Atara Biotherapeutics, Inc. (ATRA) scores 22 out of 100 on boothcheck's 11-model valuation framework. Verdict: Strong Avoid The estimated fair value is $69.69, representing a 1338% margin of safety. Quantitative score: 40/100. Qualitative score: 20/100.

Analysis includes bear, base, and bull fair value targets using DCF, Graham, regression, and 8 other valuation models.

View full ATRA analysis on boothcheck